Michele Y. Halyard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michele Y. Halyard has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Eleanor E. R. Harris
Department of Radiation Oncology, St. Luke's University Health Network, Easton, Pennsylvania
3 shared publications Lisa Bailey
3 shared publicationsSamir H. Patel
Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA
3 shared publications- Sharad Goyal
Department of Radiation Oncology, School of Medicine and Health Sciences, George Washington University, Washington, DC 20052, USA
3 shared publications Amylou C. Dueck
Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona, USA
2 shared publicationsAngelina D. Tan
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications
Latest Publications
- Open Access
- 16 January 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (7) , 8767-8776
“There's not enough studies”: Views of black breast and ovarian cancer patients on research participation
Background: Black breast and ovarian cancer patients are underrepresented in clinical cancer trials disproportionate to the prevalence of these cancers in Black females. Historically, lower enrollment has been attributed to individualized factors, including medical mistrust, but more recently structural factors, including systemic racism, have received additional scrutiny. We interviewed Black women with a personal or family history of breast and ovarian cancer to understand their views and experiences related to research participation.Methods: Qualitative interviews were conducted via telephone or video conference and transcribed verbatim. Transcripts were qualitatively analyzed for iterative themes related to the offer and participation in cancer clinical trials and research studies, impact on cancer care, and recommendations to increase enrollment of Black patients.Results: Sixty‐one Black women completed an interview. Participants expressed that Black women are underrepresented in cancer research, and that this negatively impacted their own care. Many cited past historical abuses, including the Tuskegee syphilis trial, as a potential factor for lower enrollment but suggested that lower enrollment was better understood in the context of the entirety of their healthcare experiences, including present‐day examples of patient mistreatment or dismissal. Participants suggested that proactive community engagement, transparency, and increased representation of Black research team members were strategies likely to foster trust and bolster research participation.Conclusion(s): Medical mistrust is only a partial factor in the lower participation of Black patients in cancer research. Researchers should implement the strategies identified by our participants to promote diverse enrollment and ensure that Black patients are included in future therapeutic advances.
- 16 January 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (7) , 8767-8776
Open Access“There's not enough studies”: Views of black breast and ovarian cancer patients on research participation
Background: Black breast and ovarian cancer patients are underrepresented in clinical cancer trials disproportionate to the prevalence of these cancers in Black females. Historically, lower enrollment has been attributed to individualized factors, including medical mistrust, but more recently structural factors, including systemic racism, have received additional scrutiny. We interviewed Black women with a personal or family history of breast and ovarian cancer to understand their views and experiences related to research participation.Methods: Qualitative interviews were conducted via telephone or video conference and transcribed verbatim. Transcripts were qualitatively analyzed for iterative themes related to the offer and participation in cancer clinical trials and research studies, impact on cancer care, and recommendations to increase enrollment of Black patients.Results: Sixty‐one Black women completed an interview. Participants expressed that Black women are underrepresented in cancer research, and that this negatively impacted their own care. Many cited past historical abuses, including the Tuskegee syphilis trial, as a potential factor for lower enrollment but suggested that lower enrollment was better understood in the context of the entirety of their healthcare experiences, including present‐day examples of patient mistreatment or dismissal. Participants suggested that proactive community engagement, transparency, and increased representation of Black research team members were strategies likely to foster trust and bolster research participation.Conclusion(s): Medical mistrust is only a partial factor in the lower participation of Black patients in cancer research. Researchers should implement the strategies identified by our participants to promote diverse enrollment and ensure that Black patients are included in future therapeutic advances.
- Open Access
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , S161-S162
A Prospective Study of Mucosal Sparing Proton Beam Therapy in Resected Oropharyngeal Cancer Patients: Toxicity, Quality of Life and Swallow Function
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , S161-S162
Open AccessA Prospective Study of Mucosal Sparing Proton Beam Therapy in Resected Oropharyngeal Cancer Patients: Toxicity, Quality of Life and Swallow Function
- Open Access
- 16 July 2020
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 4 (1) , 1-8
Patient-reported quality-of-life outcomes in relation to provider-assessed adverse events during head and neck radiotherapy
Purpose: To assess the relationship between patient-reported quality-of-life (QOL) outcomes and provider-assessed adverse events (AEs) during head-and-neck (H&N) radiotherapy (RT). Methods: Sixty-five patients undergoing H&N RT prospectively completed 12-domain linear analogue self-assessments (LASA) at baseline, before biweekly appointments, and at last week of RT. At the same time points, provider-assessed AEs were graded using Common Terminology Criteria for Adverse Events v4.0. LASA scores were stratified by maximum-grade AE and analyzed using Kruskal-Wallis methodology. Agreement between LASA scores and maximum-grade AE was assessed using Bland-Altman analysis. Results: Patient-reported QOL outcomes showed clinically meaningful decreases in most domains, predominantly fatigue (77.8% of patients), social activity (75.4%), and overall QOL (74.2%). Provider-assessed AEs showed 100% grade 2 AE, 35.4% grade 3 AE, and 3.1% grade 4 AE. At baseline, patients with higher grade AEs reported worse physical well-being (WB) (P = .04). At week 1, the following QOL domains were worse for patients with higher grade AEs: overall QOL (P = .03), mental WB (P = .02), and physical WB (P = .03). Bland-Altman analysis showed that QOL scores were relatively worse than AE burden at baseline and relatively better at RT completion. Conclusions: Worse QOL was associated with higher-grade AEs at baseline and early in RT. The impact of AEs on QOL appears to lessen with time. Patient-reported QOL outcomes and provider-assessed AEs provide complementary information.
- 16 July 2020
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 4 (1) , 1-8
Open AccessPatient-reported quality-of-life outcomes in relation to provider-assessed adverse events during head and neck radiotherapy
Purpose: To assess the relationship between patient-reported quality-of-life (QOL) outcomes and provider-assessed adverse events (AEs) during head-and-neck (H&N) radiotherapy (RT). Methods: Sixty-five patients undergoing H&N RT prospectively completed 12-domain linear analogue self-assessments (LASA) at baseline, before biweekly appointments, and at last week of RT. At the same time points, provider-assessed AEs were graded using Common Terminology Criteria for Adverse Events v4.0. LASA scores were stratified by maximum-grade AE and analyzed using Kruskal-Wallis methodology. Agreement between LASA scores and maximum-grade AE was assessed using Bland-Altman analysis. Results: Patient-reported QOL outcomes showed clinically meaningful decreases in most domains, predominantly fatigue (77.8% of patients), social activity (75.4%), and overall QOL (74.2%). Provider-assessed AEs showed 100% grade 2 AE, 35.4% grade 3 AE, and 3.1% grade 4 AE. At baseline, patients with higher grade AEs reported worse physical well-being (WB) (P = .04). At week 1, the following QOL domains were worse for patients with higher grade AEs: overall QOL (P = .03), mental WB (P = .02), and physical WB (P = .03). Bland-Altman analysis showed that QOL scores were relatively worse than AE burden at baseline and relatively better at RT completion. Conclusions: Worse QOL was associated with higher-grade AEs at baseline and early in RT. The impact of AEs on QOL appears to lessen with time. Patient-reported QOL outcomes and provider-assessed AEs provide complementary information.
- 1 April 2020
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 95 (4) , 639-641
#MeToo in Health Care: A Multidimensional Problem With Widespread Effects and Incomplete Answers
- 1 April 2020
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 95 (4) , 639-641
#MeToo in Health Care: A Multidimensional Problem With Widespread Effects and Incomplete Answers
- 1 September 2019
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (9) , 1814-1824
N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2)
- 1 September 2019
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (9) , 1814-1824
N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2)
- 28 February 2017
- Published by Springer Nature in Quality of Life Research
- Vol. 26 (7) , 1721-1731
Electronic patient-reported outcomes and toxicities during radiotherapy for head-and-neck cancer
Purpose To characterize quality of life (QOL) using real-time, electronic patient-reported outcomes (ePROs) and to evaluate adverse events (AEs) and supportive care during head-and-neck radiotherapy (RT) and concurrent chemoradiotherapy (CCRT). Methods Sixty-five patients undergoing head-and-neck RT completed electronic, real-time, 12-item linear analog self-assessments (LASA) at baseline, before biweekly appointments, and at the last week of RT. Changes in QOL domains between time points were calculated. Clinical data were collected from the institutional medical record. AEs were recorded at the same time points as the LASA and graded. Results During head-and-neck RT, most patients had clinically meaningful decreases in all QOL domains except level of support, financial concerns, and legal concerns. QOL domains with the most prevalent, clinically meaningful decreases were fatigue (75.4% of patients; 95% CI, 62.9–84.9%), social activity (70.8%; 95% CI, 58.0–81.1%), and overall QOL (70.8%; 95% CI, 58.0–81.1%). All patients had grade 2 AEs; 35.4% had grade 3 (50.0%, CCRT; 12.0%, RT; P = .002). Weight loss averaged 5.5 kg (6.9 kg, CCRT; 2.8 kg, RT; P < .001). Intravenous hydration was needed in 52.3% (77.5%, CCRT; 12.0%, RT; P < .001); feeding tube placement 40.0% (57.5%, CCRT; 12.0%, RT; P = .001); emergency department visits without hospitalization, 10.8%; and emergent hospitalization, 27.7% (37.5%, CCRT; 12.0%, RT; P = .04). Conclusions Head-and-neck RT, particularly CCRT, negatively impacts patients’ overall QOL, social activity, and fatigue, with frequent grade 3 AEs, weight loss, intravenous hydration, feeding tube placement, ED visits, and hospitalization. Real-time ePROs allow providers to monitor QOL at multiple time points during RT, potentially allowing early intervention to improve QOL and mitigate AEs.
- 28 February 2017
- Published by Springer Nature in Quality of Life Research
- Vol. 26 (7) , 1721-1731
Electronic patient-reported outcomes and toxicities during radiotherapy for head-and-neck cancer
Purpose To characterize quality of life (QOL) using real-time, electronic patient-reported outcomes (ePROs) and to evaluate adverse events (AEs) and supportive care during head-and-neck radiotherapy (RT) and concurrent chemoradiotherapy (CCRT). Methods Sixty-five patients undergoing head-and-neck RT completed electronic, real-time, 12-item linear analog self-assessments (LASA) at baseline, before biweekly appointments, and at the last week of RT. Changes in QOL domains between time points were calculated. Clinical data were collected from the institutional medical record. AEs were recorded at the same time points as the LASA and graded. Results During head-and-neck RT, most patients had clinically meaningful decreases in all QOL domains except level of support, financial concerns, and legal concerns. QOL domains with the most prevalent, clinically meaningful decreases were fatigue (75.4% of patients; 95% CI, 62.9–84.9%), social activity (70.8%; 95% CI, 58.0–81.1%), and overall QOL (70.8%; 95% CI, 58.0–81.1%). All patients had grade 2 AEs; 35.4% had grade 3 (50.0%, CCRT; 12.0%, RT; P = .002). Weight loss averaged 5.5 kg (6.9 kg, CCRT; 2.8 kg, RT; P < .001). Intravenous hydration was needed in 52.3% (77.5%, CCRT; 12.0%, RT; P < .001); feeding tube placement 40.0% (57.5%, CCRT; 12.0%, RT; P = .001); emergency department visits without hospitalization, 10.8%; and emergent hospitalization, 27.7% (37.5%, CCRT; 12.0%, RT; P = .04). Conclusions Head-and-neck RT, particularly CCRT, negatively impacts patients’ overall QOL, social activity, and fatigue, with frequent grade 3 AEs, weight loss, intravenous hydration, feeding tube placement, ED visits, and hospitalization. Real-time ePROs allow providers to monitor QOL at multiple time points during RT, potentially allowing early intervention to improve QOL and mitigate AEs.
- 1 June 2015
- Vol. 29 (6) , 446-58, 460
ACR Appropriateness Criteria® Ductal Carcinoma in Situ.
Ductal carcinoma in situ (DCIS) is a breast neoplasm with potential for progression to invasive cancer. Management commonly involves excision, radiotherapy, and hormonal therapy. Surgical assessment of regional lymph nodes is rarely indicated except in cases of microinvasion or mastectomy. Radiotherapy is employed for local control in breast conservation, although it may be omitted for select low-risk situations. Several radiotherapy techniques exist beyond standard whole-breast irradiation (ie, partial-breast irradiation [PBI], hypofractionated whole-breast radiation); evidence for these is evolving. We present an update of the American College of Radiology (ACR) Appropriateness Criteria® for the management of DCIS. The ACR Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions, which are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review includes an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi technique) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
- 1 June 2015
- Vol. 29 (6) , 446-58, 460
ACR Appropriateness Criteria® Ductal Carcinoma in Situ.
Ductal carcinoma in situ (DCIS) is a breast neoplasm with potential for progression to invasive cancer. Management commonly involves excision, radiotherapy, and hormonal therapy. Surgical assessment of regional lymph nodes is rarely indicated except in cases of microinvasion or mastectomy. Radiotherapy is employed for local control in breast conservation, although it may be omitted for select low-risk situations. Several radiotherapy techniques exist beyond standard whole-breast irradiation (ie, partial-breast irradiation [PBI], hypofractionated whole-breast radiation); evidence for these is evolving. We present an update of the American College of Radiology (ACR) Appropriateness Criteria® for the management of DCIS. The ACR Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions, which are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review includes an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi technique) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 6064
Outcomes of head and neck squamous cell carcinomas (HNSCC) treated with reirradiation (RRT) at Mayo Clinic.
6064 Background: RRT is offered as definitive (DRRT) or post-operative (PRRT) treatment for patients (pts) with loco-regionally recurrent (LRR) or new primary (NP) HNSCC in previously irradiated volumes. We report the results of a retrospective chart review of all consecutive pts with LRR and NP HNSCC treated with DRRT and PRRT at Mayo Clinic. Methods: We included LRR and NP HNSCC pts treated with DRRT/PRRT from 2003-2011 at all Mayo Clinic campuses. Patient and treatment related data were collected. Loco-regional recurrence rate (LR) and distant metastases rate (DM) at 2 years, and overall survival (OS) from end of RRT using Kaplan-Meier methods, were calculated. Results: We identified 89 pts (68 M, 21 F). 67 pts had LRR; 22 NP. Treatment included salvage surgery with PRRT (47 pts) and DRRT (42 pts). 30 pts received concurrent chemotherapy (CT) with PRRT; 33 DRRT pts received CT. Median prior RT dose was 66 Gy (26.4 – 79.2 Gy). Median PRRT dose was 60 Gy (11 – 70 Gy). Median DRRT dose was 69.6 Gy (18 – 7...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 6064
Outcomes of head and neck squamous cell carcinomas (HNSCC) treated with reirradiation (RRT) at Mayo Clinic.
6064 Background: RRT is offered as definitive (DRRT) or post-operative (PRRT) treatment for patients (pts) with loco-regionally recurrent (LRR) or new primary (NP) HNSCC in previously irradiated volumes. We report the results of a retrospective chart review of all consecutive pts with LRR and NP HNSCC treated with DRRT and PRRT at Mayo Clinic. Methods: We included LRR and NP HNSCC pts treated with DRRT/PRRT from 2003-2011 at all Mayo Clinic campuses. Patient and treatment related data were collected. Loco-regional recurrence rate (LR) and distant metastases rate (DM) at 2 years, and overall survival (OS) from end of RRT using Kaplan-Meier methods, were calculated. Results: We identified 89 pts (68 M, 21 F). 67 pts had LRR; 22 NP. Treatment included salvage surgery with PRRT (47 pts) and DRRT (42 pts). 30 pts received concurrent chemotherapy (CT) with PRRT; 33 DRRT pts received CT. Median prior RT dose was 66 Gy (26.4 – 79.2 Gy). Median PRRT dose was 60 Gy (11 – 70 Gy). Median DRRT dose was 69.6 Gy (18 – 7...
- Open Access
- 1 April 2015
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 7, 449-458
Benefits, risks, and safety of external beam radiation therapy for breast cancer
Breast cancer is a common and complex disease often necessitating multimodality care. Breast cancer may be treated with surgical resection, radiotherapy (RT), and systemic therapy, including chemotherapy, hormonal therapy, and targeted therapies, or a combination thereof. In the past 50 years, RT has played an increasingly significant role in the treatment of breast cancer, resulting in improvements in locoregional control and survival for women undergoing mastectomy who are at high risk of recurrence, and allowing for breast conservation in certain settings. Although radiation provides significant benefit to many women with breast cancer, it is also associated with risks of toxicity, including cardiac and pulmonary toxicity, lymphedema, and secondary malignancy. RT techniques have advanced and continue to evolve dramatically, offering increased precision and reproducibility of treatment delivery and flexibility of treatment schedule. This increased sophistication of RT offers promise of improved outcomes by maintaining or improving efficacy, reducing toxicity, and increasing patient access and convenience. A review of the role of radiation therapy in breast cancer, its associated toxicities and efforts in toxicity reduction is presented.
- 1 April 2015
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 7, 449-458
Open AccessBenefits, risks, and safety of external beam radiation therapy for breast cancer
Breast cancer is a common and complex disease often necessitating multimodality care. Breast cancer may be treated with surgical resection, radiotherapy (RT), and systemic therapy, including chemotherapy, hormonal therapy, and targeted therapies, or a combination thereof. In the past 50 years, RT has played an increasingly significant role in the treatment of breast cancer, resulting in improvements in locoregional control and survival for women undergoing mastectomy who are at high risk of recurrence, and allowing for breast conservation in certain settings. Although radiation provides significant benefit to many women with breast cancer, it is also associated with risks of toxicity, including cardiac and pulmonary toxicity, lymphedema, and secondary malignancy. RT techniques have advanced and continue to evolve dramatically, offering increased precision and reproducibility of treatment delivery and flexibility of treatment schedule. This increased sophistication of RT offers promise of improved outcomes by maintaining or improving efficacy, reducing toxicity, and increasing patient access and convenience. A review of the role of radiation therapy in breast cancer, its associated toxicities and efforts in toxicity reduction is presented.
- 1 February 2014
- Vol. 28 (2) , 157-64, C3
ACR Appropriateness Criteria local-regional recurrence (LRR) and salvage surgery-breast cancer.
Although both breast-conserving surgery and mastectomy generally provide excellent local-regional control of breast cancer, local-regional recurrence (LRR) does occur. Predictors for LRR include patient, tumor, and treatment-related factors. Salvage after LRR includes coordination of available modalities, including surgery, radiation, chemotherapy, and hormonal therapy, depending on the clinical scenario. Management recommendations for breast cancer LRR, including patient scenarios, are reviewed, and represent evidence-based data and expert opinion of the American College of Radiology Appropriateness Criteria Expert Panel on LRR.The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel.The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
- 1 February 2014
- Vol. 28 (2) , 157-64, C3
ACR Appropriateness Criteria local-regional recurrence (LRR) and salvage surgery-breast cancer.
Although both breast-conserving surgery and mastectomy generally provide excellent local-regional control of breast cancer, local-regional recurrence (LRR) does occur. Predictors for LRR include patient, tumor, and treatment-related factors. Salvage after LRR includes coordination of available modalities, including surgery, radiation, chemotherapy, and hormonal therapy, depending on the clinical scenario. Management recommendations for breast cancer LRR, including patient scenarios, are reviewed, and represent evidence-based data and expert opinion of the American College of Radiology Appropriateness Criteria Expert Panel on LRR.The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel.The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.